Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases

Neuromuscular Disorders

Volumn 22, Issue 11, 2012, Pages 1006-1014

  Delfín, Dawn A ^a   Zang, Kara E ^a   Schill, Kevin E ^a   Patel, Nikita T ^a   Janssen, Paul M L ^a   Raman, Subha V ^a   Rafael Fortney, Jill A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Duchenne muscular dystrophy; Heart failure; Matrix metalloproteinases; Mdx; MMP 9; MMPs; Remodeling; TIMP; TIMP 2; Tissue inhibitors of matrix metalloproteinases; Utrophin

Indexed keywords

COLLAGEN TYPE 1; DYSTROPHIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; STROMELYSIN; UTROPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; FIBROBLAST; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE CONTRACTILE FORCE; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; IMMUNOBLOTTING; MALE; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; ZYMOGRAPHY;

ANIMALS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DYSTROPHIN; FEMALE; HEART FAILURE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MICE, KNOCKOUT; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; UTROPHIN;

EID: 84868110238     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.05.002     Document Type: Article

References (49)

1. Finsterer J., Stollberger C. The heart in human dystrophinopathies. Cardiology 2003, 99:1-19.
2. Markham L.W., Spicer R.L., Cripe L.H. The heart in muscular dystrophy. Pediatr Ann 2005, 34:531-535.
3. Zheng Q.S., Guo W.G., Lu Z.F., Shi X.Q., Su F.F., Li H. Dystrophin: from non-ischemic cardiomyopathy to ischemic cardiomyopathy. Med Hypotheses 2008, 71:434-438.
4. Townsend D., Yasuda S., Li S., Chamberlain J.S., Metzger J.M. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 2008, 16:832-835.
5. Duan D. Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet 2006, 15 Spec No 2:R253-R261.
6. Miniño A.M., Heron M.P., Murphy S.L., Kochanek K.D. Deaths: final data for 2004. Natl Vital Stat Rep 2007, 55:1-119.
7. Fedak P.W., Verma S., Weisel R.D., Li R.K. Cardiac remodeling and failure: from molecules to man (Part I). Cardiovasc Pathol 2005, 14:1-11.
8. Berk B.C., Fujiwara K., Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007, 117:568-575.
9. Polyakova V., Loeffler I., Hein S., et al. Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles. Int J Cardiol 2010, 151:18-33.
10. Janssen P.M., Hiranandani N., Mays T.A., Rafael-Fortney J.A. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 2005, 289:H2373-H2378.
11. Hainsey T.A., Senapati S., Kuhn D.E., Rafael J.A. Cardiomyopathic features associated with muscular dystrophy are independent of dystrophin absence in cardiovasculature. Neuromuscul Disord 2003, 13:294-302.
12. Deconinck A.E., Rafael J.A., Skinner J.A., et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997, 90:717-727.
13. Grady R.M., Teng H., Nichol M.C., Cunningham J.C., Wilkinson R.S., Sanes J.R. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 1997, 90:729-738.
14. Fedak P.W., Verma S., Weisel R.D., Li R.K. Cardiac remodeling and failure from molecules to man (Part II). Cardiovasc Pathol 2005, 14:49-60.
15. Buralli S., Dini F.L., Ballo P., et al. Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol 2010, 105:853-856.
16. Kitaoka H., Kubo T., Okawa M., et al. Impact of metalloproteinases on left ventricular remodeling and heart failure events in patients with hypertrophic cardiomyopathy. Circ J 2010, 74:1191-1196.
17. Muller A.L., Dhalla N.S. Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev 2012, 17:395-409.
18. Deschamps A.M., Spinale F.G. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 2006, 69:666-676.
19. Gallagher G.L., Jackson C.J., Hunyor S.N. Myocardial extracellular matrix remodeling in ischemic heart failure. Front Biosci 2007, 12:1410-1419.
20. Graham H.K., Horn M., Trafford A.W. Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol 2008, 194:3-21.
21. Janssens S., Lijnen H.R. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?. Cardiovasc Res 2006, 69:585-594.
22. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-573.
23. Cheung C., Marchant D., Walker E.K., et al. Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 2008, 117:1574-1582.
24. Brew K., Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010, 1803:55-71.
25. Dorman G., Kocsis-Szommer K., Spadoni C., Ferdinandy P. MMP inhibitors in cardiac diseases: an update. Recent Pat Cardiovasc Drug Discov 2007, 2:186-194.
26. Bani C., Lagrota-Candido J., Pinheiro D.F., et al. Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice. Muscle Nerve 2008, 37:583-592.
27. Li H., Mittal A., Makonchuk D.Y., Bhatnagar S., Kumar A. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet 2009, 18:2584-2598.
28. Fukushima K., Nakamura A., Ueda H., et al. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskelet Disord 2007, 8:54.
29. Zanotti S., Gibertini S., Mora M. Altered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-beta1 treatment. Cell Tissue Res 2010, 339:397-410.
30. Leite P.E., Lagrota-Candido J., Moraes L., et al. Nicotinic acetylcholine receptor activation reduces skeletal muscle inflammation of mdx mice. J Neuroimmunol 2010, 227:44-51.
31. Miyazaki D., Nakamura A., Fukushima K., Yoshida K., Takeda S., Ikeda S. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum Mol Genet 2011, 20:1787-1799.
32. Nevo Y., Aga-Mizrachi S., Elmakayes E., et al. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. PLoS One 2011, 6:e18049.
33. Dahiya S., Bhatnagar S., Hindi S.M., et al. Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice. Hum Mol Genet 2011, 20:4345-4359.
34. Nadarajah V.D., van Putten M., Chaouch A., et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 2011, 21:569-578.
35. Au C.G., Butler T.L., Sherwood M.C., Egan J.R., North K.N., Winlaw D.S. Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. Int J Exp Pathol 2011, 92:57-65.
36. Dahiya S., Givvimani S., Bhatnagar S., Qipshidze N., Tyagi S.C., Kumar A. Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. J Immunol 2011, 187:2723-2731.
37. Sanford J.L., Edwards J.D., Mays T.A., Gong B., Merriam A.P., Rafael-Fortney J.A. Claudin-5 localizes to the lateral membranes of cardiomyocytes and is altered in utrophin/dystrophin-deficient cardiomyopathic mice. J Mol Cell Cardiol 2005, 38:323-332.
38. Puchalski M.D., Williams R.V., Askovich B., et al. Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy?. Int J Cardiovasc Imaging 2009, 25:57-63.
39. Hawkes S.P., Li H., Taniguchi G.T. Zymography and reverse zymography for detecting MMPs and TIMPs. Methods Mol Biol: Matrix Metalloproteinase Protoc 2010, 622:257-269.
40. Verhaert D., Richards K., Rafael-Fortney J.A., Raman S.V. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging 2011, 4:67-76.
41. Bujak M., Dobaczewski M., Chatila K., et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 2008, 173:57-67.
42. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278.
43. Schwartzkopff B., Fassbach M., Pelzer B., Brehm M., Strauer B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002, 4:439-444.
44. Creemers E.E., Davis J.N., Parkhurst A.M., et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2003, 284:H364-H371.
45. Kandalam V., Basu R., Abraham T., et al. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res 2010, 106:796-808.
46. Anilkumar N., Sirker A., Shah A.M. Redox sensitive signaling pathways in cardiac remodeling, hypertrophy and failure. Front Biosci 2009, 14:3168-3187.
47. Ishihara H., Kubota H., Lindberg R.L., et al. Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol 2008, 67:435-448.
48. Rafael J.A., Tinsley J.M., Potter A.C., Deconinck A.E., Davies K.E. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet 1998, 19:79-82.
49. Rafael-Fortney J.A., Chimanji N.S., Schill K.E., et al. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation 2011, 124:582-588.